Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD), after negotiations with the FDA.
Boehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, as price competition began to affect its biggest selling drug Spiriva.<
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
